EMMA Emmaus Life Sciences, Inc. revenue, earnings and financials
For the quarter ended June 30, 2026, Emmaus Life Sciences, Inc. reported revenue of $6.32M (up 124.3% from a year earlier), net income of $1.34M and diluted EPS of $0.02; over the last four quarters revenue was $15.5M and net income −$6.02M; for the fiscal year ended December 2025 revenue was $12.5M, down 25.2% on the year before.
EMMA annual revenue and earnings
- Fiscal year ended Dec 2025: revenue $12.5M, gross profit $11.6M, operating income $231K, net income −$7.49M (margin -60.2%), EPS −$0.12
- Fiscal year ended Dec 2024: revenue $16.7M, gross profit $15.5M, operating income −$1.89M, net income −$6.45M (margin -38.7%), EPS −$0.10
- Fiscal year ended Dec 2023: revenue $29.6M, gross profit $28.3M, operating income $3.54M, net income −$3.73M (margin -12.6%), EPS −$0.07
- Fiscal year ended Dec 2022: revenue $18.4M, gross profit $15.8M, operating income −$6.59M, net income −$10.6M (margin -57.8%), EPS −$0.21
- Fiscal year ended Dec 2021: revenue $20.6M, gross profit $17.3M, operating income −$6.13M, net income −$15.9M (margin -77.4%), EPS −$0.32
EMMA quarterly revenue and earnings
- Quarter ended Jun 30, 2026: revenue $6.32M (up 124.3% year over year), net income $1.34M, EPS $0.02
- Quarter ended Mar 31, 2026: revenue $1.98M (down 17.6% year over year), net income −$3.34M, EPS −$0.05
- Quarter ended Dec 31, 2025 (from the annual report): revenue $3.85M (up 17.0% year over year), net income −$1.95M, EPS −$0.03
- Quarter ended Sep 30, 2025: revenue $3.38M (down 38.3% year over year), net income −$2.08M, EPS −$0.03
- Quarter ended Jun 30, 2025: revenue $2.82M (down 47.6% year over year), net income −$1.14M, EPS −$0.02
- Quarter ended Mar 31, 2025: revenue $2.41M (down 4.0% year over year), net income −$2.33M, EPS −$0.04
- Quarter ended Dec 31, 2024 (from the annual report): revenue $3.29M (down 53.4% year over year), net income −$1.75M, EPS −$0.03
- Quarter ended Sep 30, 2024: revenue $5.48M (up 9.2% year over year), net income $1.83M, EPS $0.03
- Quarter ended Jun 30, 2024: revenue $5.38M (down 50.0% year over year), net income −$2.18M, EPS −$0.03
- Quarter ended Mar 31, 2024: revenue $2.51M (down 62.9% year over year), net income −$4.35M, EPS −$0.07
- Quarter ended Dec 31, 2023 (from the annual report): revenue $7.07M (up 19.2% year over year), net income $1.21M, EPS $0.04
- Quarter ended Sep 30, 2023: revenue $5.02M (up 1.6% year over year), net income $67.0K, EPS −$0.01
- Quarter ended Jun 30, 2023: revenue $10.8M (up 151.0% year over year), net income −$1.56M, EPS −$0.03
- Quarter ended Mar 31, 2023: revenue $6.75M (up 108.8% year over year), net income −$3.45M, EPS −$0.07
- Quarter ended Dec 31, 2022 (from the annual report): revenue $5.93M (up 96.4% year over year), net income $200K, EPS $0.01
- Quarter ended Sep 30, 2022: revenue $4.94M (down 14.3% year over year), net income −$391K, EPS −$0.01
- Quarter ended Jun 30, 2022: revenue $4.29M (down 33.9% year over year), net income −$8.89M, EPS −$0.18
- Quarter ended Mar 31, 2022: revenue $3.23M (down 39.4% year over year), net income −$1.54M, EPS −$0.03
- Quarter ended Dec 31, 2021 (from the annual report): revenue $3.02M, net income −$6.86M, EPS −$0.14
- Quarter ended Sep 30, 2021: revenue $5.77M, net income −$3.15M, EPS −$0.06
EMMA cash flow, buybacks and dividends
- Fiscal year ended Dec 2025: operating cash flow −$11.0K, share buybacks n/a
- Fiscal year ended Dec 2024: operating cash flow −$2.29M, share buybacks n/a
- Fiscal year ended Dec 2023: operating cash flow −$1.50M, share buybacks n/a
- Fiscal year ended Dec 2022: operating cash flow −$5.07M, share buybacks n/a
- Fiscal year ended Dec 2021: operating cash flow −$1.25M, share buybacks n/a
EMMA balance sheet
- Jun 30, 2026: cash $2.81M, total assets $16.4M, total liabilities $82.5M, shareholders' equity −$66.2M
- Mar 31, 2026: cash $1.07M, total assets $18.7M, total liabilities $86.6M, shareholders' equity −$67.9M
- Dec 31, 2025: cash $2.13M, total assets $21.4M, total liabilities $85.0M, shareholders' equity −$63.6M
- Sep 30, 2025: cash $293K, total assets $20.8M, total liabilities $80.2M, shareholders' equity −$59.5M
- Jun 30, 2025: cash $886K, total assets $23.3M, total liabilities $79.0M, shareholders' equity −$55.7M
- Mar 31, 2025: cash $1.33M, total assets $22.5M, total liabilities $81.1M, shareholders' equity −$58.6M
- Dec 31, 2024: cash $1.39M, total assets $23.6M, total liabilities $80.1M, shareholders' equity −$56.5M
- Sep 30, 2024: cash $1.26M, total assets $27.3M, total liabilities $81.1M, shareholders' equity −$53.8M
What is EMMA's revenue?
Emmaus Life Sciences, Inc. reported $15.5M of revenue over its last four quarters, through June 30, 2026.
Is EMMA profitable?
No. Emmaus Life Sciences, Inc. lost $6.02M over the last four quarters.
What is EMMA's EPS?
Diluted earnings per share over the last four quarters were −$0.09; $0.02 in the latest quarter.